Ocular Therapeutix Stock Current Ratio

OCUL Stock  USD 9.09  0.26  2.94%   
Ocular Therapeutix fundamentals help investors to digest information that contributes to Ocular Therapeutix's financial success or failures. It also enables traders to predict the movement of Ocular Stock. The fundamental analysis module provides a way to measure Ocular Therapeutix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocular Therapeutix stock.
Last ReportedProjected for Next Year
Current Ratio 6.66  8.73 
Current Ratio is expected to rise to 8.73 this year.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ocular Therapeutix Company Current Ratio Analysis

Ocular Therapeutix's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Ocular Therapeutix Current Ratio

    
  6.14 X  
Most of Ocular Therapeutix's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocular Therapeutix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Ocular Current Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for Ocular Therapeutix is extremely important. It helps to project a fair market value of Ocular Stock properly, considering its historical fundamentals such as Current Ratio. Since Ocular Therapeutix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ocular Therapeutix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ocular Therapeutix's interrelated accounts and indicators.
0.77-0.87-0.840.70.760.770.750.920.410.620.650.230.160.80.910.660.610.920.950.87
0.77-0.61-0.680.650.680.610.20.810.50.880.570.240.170.480.620.320.670.630.610.59
-0.87-0.610.73-0.44-0.65-0.74-0.79-0.91-0.36-0.36-0.46-0.17-0.28-0.58-0.74-0.75-0.34-0.89-0.95-0.79
-0.84-0.680.73-0.86-0.96-0.92-0.69-0.87-0.15-0.64-0.82-0.210.24-0.9-0.94-0.41-0.57-0.87-0.85-0.91
0.70.65-0.44-0.860.790.710.410.620.110.770.940.41-0.310.820.870.210.640.670.610.7
0.760.68-0.65-0.960.790.910.60.850.10.630.740.11-0.30.880.860.280.570.810.770.88
0.770.61-0.74-0.920.710.910.690.870.090.420.59-0.09-0.040.810.860.260.420.890.820.94
0.750.2-0.79-0.690.410.60.690.690.120.050.420.030.040.760.780.680.240.810.880.81
0.920.81-0.91-0.870.620.850.870.690.420.590.560.090.160.710.830.570.560.90.920.88
0.410.5-0.36-0.150.110.10.090.120.420.320.07-0.010.490.010.170.450.680.170.280.13
0.620.88-0.36-0.640.770.630.420.050.590.320.730.49-0.20.510.580.260.650.420.420.42
0.650.57-0.46-0.820.940.740.590.420.560.070.730.58-0.40.780.820.30.620.640.60.62
0.230.24-0.17-0.210.410.11-0.090.030.09-0.010.490.58-0.170.20.250.420.180.110.19-0.04
0.160.17-0.280.24-0.31-0.3-0.040.040.160.49-0.2-0.4-0.17-0.27-0.110.250.040.110.14-0.08
0.80.48-0.58-0.90.820.880.810.760.710.010.510.780.2-0.270.940.370.550.820.790.87
0.910.62-0.74-0.940.870.860.860.780.830.170.580.820.25-0.110.940.490.590.910.90.92
0.660.32-0.75-0.410.210.280.260.680.570.450.260.30.420.250.370.490.250.490.70.38
0.610.67-0.34-0.570.640.570.420.240.560.680.650.620.180.040.550.590.250.450.450.45
0.920.63-0.89-0.870.670.810.890.810.90.170.420.640.110.110.820.910.490.450.960.95
0.950.61-0.95-0.850.610.770.820.880.920.280.420.60.190.140.790.90.70.450.960.91
0.870.59-0.79-0.910.70.880.940.810.880.130.420.62-0.04-0.080.870.920.380.450.950.91
Click cells to compare fundamentals

Ocular Current Ratio Historical Pattern

Today, most investors in Ocular Therapeutix Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ocular Therapeutix's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ocular Therapeutix current ratio as a starting point in their analysis.
   Ocular Therapeutix Current Ratio   
       Timeline  
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

Ocular Price To Sales Ratio

Price To Sales Ratio

5.79

At this time, Ocular Therapeutix's Price To Sales Ratio is quite stable compared to the past year.
In accordance with the recently published financial statements, Ocular Therapeutix has a Current Ratio of 6.14 times. This is 111.0% higher than that of the Pharmaceuticals sector and 12.29% lower than that of the Health Care industry. The current ratio for all United States stocks is 184.26% lower than that of the firm.

Ocular Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocular Therapeutix's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocular Therapeutix could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics of similar companies.
Ocular Therapeutix is currently under evaluation in current ratio category among its peers.

Ocular Therapeutix Current Valuation Drivers

We derive many important indicators used in calculating different scores of Ocular Therapeutix from analyzing Ocular Therapeutix's financial statements. These drivers represent accounts that assess Ocular Therapeutix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ocular Therapeutix's important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap178.8M1.3B532.5M216.0M356.0M238.3M
Enterprise Value183.7M1.1B427.3M178.0M243.6M200.8M

Ocular Therapeutix ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ocular Therapeutix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ocular Therapeutix's managers, analysts, and investors.
Environmental
Governance
Social

Ocular Fundamentals

About Ocular Therapeutix Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
Check out Ocular Therapeutix Piotroski F Score and Ocular Therapeutix Altman Z Score analysis.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.29)
Revenue Per Share
0.529
Quarterly Revenue Growth
0.083
Return On Assets
(0.22)
Return On Equity
(0.73)
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.